Skip to main content

Biodesix Closes $8.3M Financing Round

NEW YORK (GenomeWeb News) – Biodesix today said that it has closed an $8.3 million Series E round of private financing.

The Boulder, Colo.-based molecular diagnostics firm said that new funds accounted for $4.3 million of the financing round, while the remaining $4 million came from the conversion of a convertible note. It said that all of the funds came from existing shareholders in the firm.

Biodesix plans to use the funding to support ongoing development of its technology platform and to expand sales and marketing efforts for its first product, the VeriStrat proteomic biomarker test, which is intended to help physicians guide therapy for patients with advanced non-small cell lung cancer.

In June the firm announced that it had secured Medicare coverage for the VeriStrat test.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.